Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Cyclically Adjusted PB Ratio: (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603229 Zhejiang Ausun Pharmaceutical Co Ltd SHSE:603229
76 GF Score
Price ¥7.73
GF Value ¥10.54
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Zhejiang Ausun Pharmaceutical Co Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zhejiang Ausun Pharmaceutical Co  (SHSE:603229) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Zhejiang Ausun Pharmaceutical Co Cyclically Adjusted PB Ratio Related Terms


Zhejiang Ausun Pharmaceutical Co Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Zhejiang Ausun Pharmaceutical Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Ausun Pharmaceutical Co Cyclically Adjusted PB Ratio Chart

Zhejiang Ausun Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 7.26 6.03

Zhejiang Ausun Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.75 6.46 6.03 6.02 0.00

SHSE:603229 vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Zhejiang Ausun Pharmaceutical Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Ausun Pharmaceutical Co Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhejiang Ausun Pharmaceutical Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zhejiang Ausun Pharmaceutical Co's Cyclically Adjusted PB Ratio falls into.


SHSE:603229
76GF Score
Zhejiang Ausun Pharmaceutical Co Ltd SHSE:603229
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Ausun Pharmaceutical Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Zhejiang Ausun Pharmaceutical Co's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Zhejiang Ausun Pharmaceutical Co's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.015/116.0564*116.0564
=3.015

Current CPI (Jun. 2026) = 116.0564.

Zhejiang Ausun Pharmaceutical Co Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.000 102.400 0.000
201612 0.440 102.600 0.498
201703 0.346 103.200 0.389
201706 0.727 103.100 0.818
201709 0.737 104.100 0.822
201712 0.766 104.500 0.851
201803 0.769 105.300 0.848
201806 0.783 104.900 0.866
201809 0.795 106.600 0.866
201812 0.810 106.500 0.883
201903 0.821 107.700 0.885
201906 0.840 107.700 0.905
201909 0.866 109.800 0.915
201912 0.875 111.200 0.913
202003 0.903 112.300 0.933
202006 0.930 110.400 0.978
202009 0.887 111.700 0.922
202012 1.431 111.500 1.489
202103 1.486 112.662 1.531
202106 1.535 111.769 1.594
202109 1.548 112.215 1.601
202112 1.593 113.108 1.635
202203 1.683 114.335 1.708
202206 1.712 114.558 1.734
202209 1.781 115.339 1.792
202212 1.855 115.116 1.870
202303 2.443 115.116 2.463
202306 2.523 114.558 2.556
202309 2.545 115.339 2.561
202312 2.579 114.781 2.608
202403 2.727 115.227 2.747
202406 2.796 114.781 2.827
202409 2.763 115.785 2.769
202412 2.736 114.893 2.764
202503 2.857 115.116 2.880
202506 2.921 114.907 2.950
202509 2.827 115.471 2.841
202512 2.733 115.832 2.738
202603 2.851 116.303 2.845
202606 3.015 116.056 3.015

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥7.73 is trading 26.7% below its estimated GF Value™ of ¥10.54. GuruFocus considers Zhejiang Ausun Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:603229:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ¥10.54 vs. price of ¥7.73 (26.7% below fair value)
  • GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the SHSE:603229 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang Ausun Pharmaceutical Co Business Description

Address No.5, Donghai 4th Avenue, chemical raw materials base Linhai Park East, Zhejiang Province, Taizhou, CHN, 317016
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
76GF Score

Get the complete analysis for SHSE:603229

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.73
Price
¥10.54
GF Value